A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer

被引：0
作者：
E. Esteban
González de Sande
J. Puertas
J. Fra
I. Palacio
J.M. Vieitez
J.L. Fernández
I. Muñiz
A. Modollel
J. Carrasco
M. Sala
A.J. Lacave
机构：
来源：
Breast Cancer Research and Treatment | 2000年 / 62卷
关键词：
advanced breast cancer; vinorelbine; epirubicin; cyclophosphamide; combination chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background.Vinorelbine (Navelbin®; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin®: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combination of these three agents (CEN).
引用
收藏
页码：127 / 133
页数：6
相关论文
共 50 条
[31]   Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients. [J].
Saeki T. ;
Takashima S. ;
Ogita M. ;
Tabei T. ;
Adachi I. ;
Tamura K. ;
Takatsuka Y. ;
Kanda K. .
Breast Cancer, 2006, 13 (2) :159-165
[32]   A PHASE-II STUDY OF CARBOPLATIN AND VINORELBINE AS 2ND-LINE TREATMENT FOR ADVANCED BREAST-CANCER [J].
IAFFAIOLI, RV ;
TORTORIELLO, A ;
FACCHINI, G ;
SANTANGELO, M ;
DESENA, G ;
GESUE, G ;
BUCCI, L ;
SCARAMELLINO, G ;
ANASTASIO, E ;
FINIZIO, A ;
ANTONELLI, B ;
VALLEFUOCO, V ;
MOSELLA, G ;
CAPONIGRO, F .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1256-1258
[33]   PHASE-II TRIAL OF WEEKLY IV-VINORELBINE IN FIRST-LINE ADVANCED BREAST-CANCER CHEMOTHERAPY [J].
GARCIACONDE, J ;
LLUCH, A ;
MARTIN, M ;
CASADO, A ;
GERVASIO, H ;
DEOLIVEIRA, C ;
DEPABLO, JL ;
GOROSTIAGA, J ;
GIRON, GC ;
CERVANTES, A ;
MARTINEZ, A ;
PEZOUS, N ;
DELGADO, FM ;
RUBIO, ED .
ANNALS OF ONCOLOGY, 1994, 5 (09) :854-857
[34]   The raltitrexed-vinorelbine combination:: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer [J].
Ferrero, JM ;
Chamorey, E ;
Magné, N ;
Leccia, F ;
Largillier, R ;
Namer, M ;
Milano, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) :459-464
[35]   A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer [J].
Erman, M ;
Baltali, E ;
Karaoglu, A ;
Abali, H ;
Engin, H ;
Ozisik, Y ;
Guler, N ;
Altundag, K ;
Tekuzman, G .
CANCER INVESTIGATION, 2005, 23 (03) :215-221
[36]   Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer:: results of a phase I trial [J].
Untch, M ;
Eidtmann, H ;
du Bois, A ;
Meerpohl, HG ;
Thomssen, C ;
Ebert, A ;
Harbeck, N ;
Jackisch, C ;
Heilman, V ;
Emons, G ;
Wallwiener, D ;
Wiese, W ;
Blohmer, JU ;
Höffken, K ;
Kuhn, W ;
Reichardt, P ;
Muscholl, M ;
Pauschinger, M ;
Langer, B ;
Lück, HJ .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :988-997
[37]   Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study [J].
Mavroudis, D ;
Alexopoulos, A ;
Ziras, N ;
Malamos, N ;
Kouroussis, C ;
Kakolyris, S ;
Agelaki, S ;
Kalbakis, K ;
Tsavaris, N ;
Potamianou, A ;
Rigatos, G ;
Georgoulias, V .
ANNALS OF ONCOLOGY, 2000, 11 (10) :1249-1254
[38]   Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer -: A phase II study [J].
Hausmaninger, H ;
Morack, G ;
Heinrich, B ;
Wallwiener, D ;
Höffken, K ;
Buksmaui, S ;
Krejcy, K ;
Miller, MA ;
Possinger, K .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04) :429-435
[39]   Gemcitabine plus epirubicin in advanced pancreatic cancer: A phase II multicenter trial [J].
Ianniello, GP ;
Orditura, M ;
Rossi, A ;
De Vita, F ;
Maiorino, L ;
Carrozza, F ;
Manzione, L ;
Catalano, G .
ONCOLOGY REPORTS, 2001, 8 (05) :1111-1115
[40]   Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer [J].
Bonneterre, J ;
Dieras, V ;
Tubiana-Hulin, M ;
Bougnoux, P ;
Bonneterre, ME ;
Delozier, T ;
Mayer, F ;
Culine, S ;
Dohoulou, N ;
Bendahmane, B .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1466-1471
12345